Surmodics (SRDX) Aktie Kurs

Surmodics Inc is primarily active in the healthcare and medical device industry.

The main competitors of Surmodics Inc in the market include Medtronic, Abbott Laboratories, and Boston Scientific Corporation.

Surmodics Inc, founded in 1979, is a leading provider of surface modification and in vitro diagnostic technologies. With its headquarters in Eden Prairie, Minnesota, the company develops and manufactures innovative products that enhance the performance of medical devices, improve drug delivery, and support the diagnosis of various diseases. Surmodics has a rich history of pioneering advancements in healthcare, and its expertise in surface modification has helped it establish collaborations with renowned medical device manufacturers globally. As a trusted name in the industry, Surmodics Inc continues to drive innovation and deliver solutions that positively impact patient outcomes and empower healthcare professionals worldwide.

Surmodics Inc has achieved significant milestones in its history. The company introduced its first medical device coating product, SurfaSeal, in 1985, which marked a breakthrough in the field. In 1998, Surmodics launched its first drug delivery coating called BioFX. The company developed StabilCoat Plus, a surface modification technology used in cardiovascular devices in 2003. In 2019, Surmodics received FDA approval for its SurVeil™ drug-coated balloon, offering a breakthrough treatment option for peripheral artery disease patients. With continuous innovation and dedication, Surmodics Inc strives to make impactful advancements in the medical technology industry.

Surmodics Inc is primarily present in the United States.

Surmodics Inc is a leading provider of medical device and in vitro diagnostic technologies. The company operates with a strong set of values and corporate philosophy that underpins its actions and decisions. Surmodics is committed to innovation, continuously striving to develop breakthrough solutions that positively impact patient outcomes. The company places a strong emphasis on integrity, conducting business with the highest ethical standards and fostering a culture of accountability. Surmodics also embraces collaboration, working closely with customers, partners, and internal teams to deliver the most advanced solutions. With a focus on quality, Surmodics ensures that its products meet the highest standards of reliability and performance, putting patient safety and well-being at the forefront of its operations. Overall, Surmodics Inc represents a commitment to innovation, integrity, collaboration, and quality in the medical device industry.

Analytikere sætter i øjeblikket et gennemsnitligt kursmål på 43,86 USD for Surmodics-aktien (median: 43,86 USD), svarende til +2,0 % i forhold til seneste kurs. Konsensus bygger på 9 analytikervurderinger.

Surmodics Analytikerens Kursmål 2026

7 analytikere vurderer i øjeblikket Surmodics-aktien: 0 anbefaler køb, 4 hold og 3 salg. For 2026 forventer analytikere, at Surmodics genererer omsætning på 123,01 Mio. USD og indtjening pr. aktie på -0,12 USD.

Surmodics Analytikerens Kursmål 2026

Omregnet til den aktuelle valutakurs handles Surmodics-aktien til 38,39 EUR (42,98 USD).

Surmodics-aktien (SRDX) er noteret på 2 børser, herunder: NASDAQ (SRDX), Frankfurt (SU6.F).

Surmodics Inc. is a renowned manufacturer of medical devices and products used in in vitro diagnostics, medical technology, and drug delivery. The company offers a wide range of innovative solutions based on nanotechnology and surface chemistry. Its core competencies include the development and manufacturing of medical coatings that can be applied to polymers, metals, and glass. These coatings are capable of improving the performance and extending the lifespan of medical devices and products. Surmodics Inc. also specializes in the development and manufacturing of reagents and detection devices for in vitro diagnostics, offering specialized kits and assays for quick and reliable determination of clinical parameters such as blood sugar levels or inflammation indicators. In the field of medical technology, Surmodics Inc. is mainly focused on the development of minimally invasive catheters and implants. These products are equipped with special coatings that prevent the penetration of bacteria and other pathogens, thus minimizing the risk of infections. Surmodics Inc. is also a key player in the drug delivery market, offering a wide range of products based on micro and nanotechnology. These include implants that release precisely dosed active ingredients, as well as intelligent delivery systems that automatically adapt to the individual needs of the patient. Surmodics Inc. is a strong and highly innovative company known for its continuous product development and quality assurance. The company works closely with its customers to develop individual solutions that meet their specific requirements.

forventet-omsætningen for Surmodics er 123,01 Mio. USD. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.

forventet-overskuddet for Surmodics er -1,72 Mio. USD. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.

Pris-til-indtjening-forholdet (P/E) for Surmodics er i øjeblikket -356,44. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Surmodics-aktien.

Pris-til-salgs-forholdet (P/S) for Surmodics er i øjeblikket 4,97. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for Surmodics-aktien.

AlleAktien-kvalitetsscore for Surmodics er 2/10.

ISIN for Surmodics er US8688731004. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.

WKN for Surmodics er 914178. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.

Tickeren for Surmodics er SRDX. Tickersymbolet bruges til at handle Surmodics-aktier på børsen.